Lloyd Rowland - Sep 20, 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
General Counsel
Signature
/s/ Lloyd Rowland
Stock symbol
CTMX
Transactions as of
Sep 20, 2023
Transactions value $
-$7,135
Form type
4
Date filed
9/22/2023, 07:12 PM
Previous filing
Mar 20, 2023
Next filing
Dec 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +15K +21.1% $0.00 86.1K Sep 20, 2023 Direct F1, F2
transaction CTMX Common Stock Sale -$7.14K -5.49K -6.37% $1.30 80.6K Sep 22, 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested.
F2 Includes 41,875 restricted stock units.
F3 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.